✦ LIBER ✦

The D-1 dopamine receptor partial agonist, CY 208–243, exhibits antiparkinsonian activity in the MPTP-treated marmoset

✍ Scribed by James A. Temlett; Piang Ngok Chong; Wolfgang H. Oertel; Peter Jenner; C. David Marsden

Book ID: 115881533
Publisher: Elsevier Science
Year: 1988
Tongue: English
Weight: 802 KB
Volume: 156
Category: Article
ISSN: 0014-2999
DOI: 10.1016/0014-2999(88)90322-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiparkinsonian activity of CY 208–243,

Antiparkinsonian activity of CY 208–243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease

✍ J. A. Temlett; N. P. Quinn; P. G. Jenner; C. D. Marsden; E. Pourcher; A.-M. Bonn 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 298 KB

The D1 agonist SKF 38393 inhibits the an

The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset

✍ Nomoto, M.; Jenner, P.; Marsden, C.D. 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 375 KB

Dopamine D1 and D2 receptor interactions

Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset

✍ Elliott, Peter J.; Walsh, Delia M.; Close, Stephen P. 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 380 KB

Effect of adding the D-1 agonist CY 208–

Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors

✍ Céline Gagnon; Baltazar Gomez-Mancilla; Rudolf Markstein; Paul J. Bédard; Thérès 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 655 KB

CY 208–243 behaves as a typical D-1 agon

CY 208–243 behaves as a typical D-1 agonist in the reserpine-treated mouse

✍ Beverley Abbott; Beryl S. Starr; Michael S. Starr 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 505 KB

Antiparkinsonian effects of the novel D3

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors

✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept